Simon Lord
Honorary Associate Professor
- Consultant Medical Oncologist, Oxford University Hospitals NHS Foundation Trust
- Senior Research Fellow, Oriel College
RESEARCH SUMMARY
My research interests focus on the development of new drugs to treat breast cancer. I also lead a number of clinical studies assessing how novel metabolic imaging signatures may reflect tumour biology.
BIOGRAPHY
Simon Lord was Director of the Early Phase Clinical Trials Unit in the Department of Oncology between 2021 and 2026. He undertook his medical oncology training in Leeds before moving to Oxford to pursue his DPhil and take up a Cancer Research UK Clinical Research Fellowship. He was appointed Senior Clinical Researcher in Experimental Cancer Therapeutics in the Department of Oncology in 2015 and is a consultant medical oncologist at the Oxford Cancer Centre. He is the Against Breast Cancer Senior Research Fellow at Oriel College.
Recent publications
Real-world obesity prevalence and history in 79 271 patients receiving systemic anticancer therapy across 13 cancer types in England (2013-2023).
Journal article
Perletta V. et al, (2026), ESMO Real World Data Digit Oncol, 12
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.
Journal article
Schmid P. et al, (2026), Clin Cancer Res
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.
Journal article
Beernaert B. et al, (2026), Sci Adv, 12
Clinical Impact of Next-Generation Sequencing-Guided Targeted Therapies in Advanced Cancer: A Systematic Review and Meta-Analysis.
Journal article
Kazmi F. et al, (2025), Clin Oncol (R Coll Radiol), 48
A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.
Journal article
Cortés J. et al, (2025), Clin Cancer Res, 31, 4953 - 4963